Tenofovir Emtricitabine
Intended to relieve viral replication in human immunodeficiency virus infection to support immune stability.
- Category
- HIV Management
- Active ingredients
- Tenofovir · Emtricitabine
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 300/200mg
Tenofovir Emtricitabine details
- Conditions
- HIV Infection · Pre-exposure Prophylaxis
- Alternative names
- Truvada
- Therapeutic class
- Antiretroviral Combination
- Pharmacological class
- Nucleoside Reverse Transcriptase Inhibitor (NRTI)
- Contraindications
- hypersensitivity to any component
- Minor side effects
- diarrhoea; nausea; fatigue; headache
- Moderate side effects
- rash; abnormal dreams
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- Gilead Sciences
- Onset Time
- 1–2 hours
- Duration
- 24 hours
- Storage instructions
- Keep in original packaging in a cool, dry place.
- Drug interactions
- didanosine; nephrotoxic medications
- Age restrictions
- Used based on adult body weight requirements.
Precautions and warnings
monitor renal function regularly; observe for signs of lactic acidosis; monitor bone mineral density
Serious side effects
lactic acidosis, requires immediate medical attention; severe hepatomegaly, requires immediate medical attention; renal impairment, requires immediate medical attention
Patient summary
intended to relieve viral replication in human immunodeficiency virus infection to support immune stability.
Mechanism of action
A combination of two nucleoside reverse transcriptase inhibitors that compete with natural substrates for binding to the viral enzyme, terminating the DNA chain and effectively slowing viral growth.
Pregnancy and breastfeeding
Pregnancy: May be used if clinically indicated. Breastfeeding: Consult a specialist, generally advised against for HIV-positive mothers.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Tenofovir Emtricitabine
Tenofovir Emtricitabine contains tenofovir and emtricitabine, widely used for HIV infection and pre-exposure prophylaxis. This combination therapy is the active formula behind the recognized brand Truvada. Designed for regular use, the product is supplied as a tablet consistently rated at 300/200mg. It offers a standard option for those managing these specific health conditions.
Tenofovir Emtricitabine availability in Asia
Tenofovir Emtricitabine is registered across 14 markets including Japan, the UAE and Singapore, with availability also in Hong Kong, Thailand and Malaysia. As a generic version of the compound originally developed by Gilead Sciences, these tablets provide an accessible option for people living or working across the region who require consistent therapy. Use of this treatment is best managed in consultation with a local medical provider to ensure individual health needs are met.